Cell Therapy News Volume 22.37 | Oct 25 2021

    By
    Justin.choi
    -
    0
    64







    2021-10-25 | CTN 22.37


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.37 – 25 October, 2021
    TOP STORY

    Nano-Optogenetic Engineering of CAR T Cells for Precision Immunotherapy with Enhanced Safety

    Investigators presented the design of light-switchable CAR T cells that allowed real-time phototunable activation of therapeutic T cells to precisely induce tumor cell killing.
    [Nature Nanotechnology]

    Abstract
    Microscopy images of pluripotent stem cells (PSCs) and PSC-derived cells for the #StemCellfie contest.
    PUBLICATIONSRanked by the impact factor of the journal

    Adoptive Cell Therapy with Tumor-Specific Th9 Cells Induces Viral Mimicry to Eliminate Antigen-Loss-Variant Tumor Cells

    Researchers demonstrated that murine and human T helper (Th) 9 cells, but not Th1/Tc1 or Th17 cells, expressing tumor-specific T cell receptors or CARs, eradicated advanced tumors that contained antigen-loss-variants.
    [Cancer Cell]

    AbstractGraphical Abstract

    Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Mitigate Oxidative Stress-Induced Senescence in Endothelial Cells via Regulation of miR-146a/Src

    In vitro results showed that mesenchymal stem cell-small extracellular vesicles reduced senescent biomarkers, decreased senescence-associated secretory phenotype, rescued angiogenesis, migration and other dysfunctions in senescent endothelial cell induced by oxidative stress.
    [Signal Transduction and Targeted Therapy]

    Full Article

    Orthogonal Design of Experiments for Optimization of Lipid Nanoparticles for mRNA Engineering of CAR T Cells

    Sequential libraries of ionizable lipid nanoparticle formulations with varied excipient compositions were screened in comparison to a standard formulation for improved mRNA delivery to T cells with low cytotoxicity, revealing B10 as the top formulation with a 3-fold increase in mRNA delivery.
    [Nano Letters]

    AbstractGraphical Abstract

    T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling Following Chemotherapy

    Investigators described a chemotherapy-induced, host-mediated mechanism that promoted remodeling of the extracellular matrix, ultimately facilitating cancer cell seeding and metastasis.
    [Cancer Research]

    Abstract

    IL12 Integrated into the CAR Exodomain Converts CD8+ T Cells to Poly-Functional NK-Like Cells with Superior Killing of Antigen-Loss Tumors

    To reprogram the functional capacities specifically of engineered CAR T cells, researchers inserted IL12 into the extracellular moiety of a CD28-ζ CAR.
    [Molecular Therapy]

    AbstractFull ArticleGraphical Abstract

    Long-Term Immune Recovery After Hematopoietic Stem Cell Transplantation for ADA Deficiency: a Single-Center Experience

    The authors found that donor engraftment in the myeloid compartment was significantly diminished in unconditioned procedures, which typically use a HLA-matched sibling donor or family donor.
    [Journal of Clinical Immunology]

    Full Article

    Angiogenic Effects of Cell Therapy within a Biomaterial Scaffold in a Rat Hind Limb Ischemia Model

    Scientists evaluated the ability of mast cells and mesencymal stem cells to induce angiogenesis in a rat model of ischemic hind limb injury on a background of a tissue engineered hydrogel scaffold.
    [Scientific Reports]

    Full Article

    Cytoplasmic CD79a Is a Promising Biomarker for B Lymphoblastic Leukemia Follow Up Post CD19 CAR-T Therapy

    Researchers investigated the efficiency and prognostic role of cytoplasmic CD79a antibody-gated multicolor flow cytometry in minimal residual disease detection in patients with B-cell acute lymphoblastic leukemia who received CD19-targeted CAR T cell therapy bridging to allogeneic hematopoietic stem cell transplantation.
    [Leukemia & Lymphoma]

    Full Article

    Survey results on the insights and hurdles of CRISPR genome editing.
    REVIEWS

    Gene Editing to Enhance the Efficacy of Cancer Cell Therapies

    The authors discuss gene editing approaches that have been the best studied in the context of human T cells and adoptive T cell therapies, summarizing their current status and near-term potential for translation.
    [Molecular Therapy]

    Abstract

    Promise and Pitfalls of Allogeneic Chimeric Antigen Receptor Therapy in Plasma Cell and Lymphoid Malignancies

    Investigators provide a comprehensive review of the challenges associated with autologous CAR, and the benefits and potential challenges associated with allogenic-CAR.
    [British Journal of Haematology]

    Abstract

    The Emerging Role of Off-the-Shelf Engineered Natural Killer Cells in Targeted Cancer Immunotherapy

    CAR-engineered natural killer (NK)-92 cells have demonstrated robust antitumor activity in in vitro and in vivo preclinical studies, propelling the clinical development of CAR NK-92 cells.
    [Molecular Therapy-Oncolytics]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

    BioCardia®, Inc. announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina.
    [BioCardia®, Inc.]

    Press Release

    Ambulero’s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation for Treatment of Severe Vascular Disease

    Ambulero, Inc. announced that the US FDA’s Office For Orphan Products Development granted the company’s request for orphan drug status for its gene therapy candidate, AMB-301, to treat Buerger’s Disease, also known as Thromboangiitis Obliterans.
    [Ambulero, Inc. (GlobeNewswire, Inc.)]

    Press Release

    SynGAP Research Fund Announces $308,000 Multidisciplinary Biomarker Grant to Boston Children’s Hospital

    The SynGAP Research Fund announced grants to Drs. April Levin, Mustafa Sahin and Annapurna Poduri of Boston Children’s Hospital to advance SYNGAP1 biomarker characterization and genotype-phenotype analysis.
    [SynGAP Research Fund]

    Press Release
    FEATURED EVENT

    FSSCR French Society for Stem Cell Research

    November 9 – 10, 2021
    Montpellier, France

    > See All Events

    JOB OPPORTUNITIES

    Director – Liver Biology

    Gordian Biotechnology – San Francisco, California, United States

    Postdoctoral Scientist – Translational Cancer Biology and Therapeutics

    Cedars-Sinai Medical Center – Los Angeles, California, United States

    Postdoctoral Fellow – Cancer Immunology & Stem Cell Engineering

    Hong Kong University – Hong Kong, China

    Postdoctoral Fellow – Hematological Trait Genomics

    Boston Children’s Hospital – Boston, Massachusetts, United States

    Assistant Editor – Cytotherapy

    The International Society for Cell & Gene Therapy – Vancouver, British Columbia, Canada

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter